Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis

Samuel M. Lindner, Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Gnter Breithardt, Kenneth W. Mahaffey, Daniel E. Singer, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Richard C. Becker, Keith A. A. Fox, Manesh R. Patel, ROCKET AF Investigators

    Research output: Contribution to journalLetterpeer-review

    22 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)1001-1003
    Number of pages3
    Issue number10
    Publication statusPublished - 7 Mar 2017

    Cite this